Genolution Inc (225220) Fair Value & Analysis
Healthcare · KR · Market cap 26.4B KRW
Fair value as of: Jul 7, 2026
From 1 valuation models · updated today
Fair value updated Jul 7, 2026 — revised from 17,038 KRW to 437.44 KRW (−97.4%) since Jun 24, 2026. Share price −13.3% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,030 KRW – 2,590 KRW · fair‑value band 288.71 KRW – 546.80 KRW · the 1,345 KRW price screens above the 437.44 KRW fair value. As of Jul 7, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Genolution Inc (225220) currently trades at 1,345 KRW, while our model-based Fair Value estimate is 437.44 KRW — implying the stock looks roughly 67.5% overvalued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Genolution Inc generated revenue of 9.8B KRW at a net margin of -91.3%. Revenue grew 20.2% year over year. It earns a return on equity of -13.5%. Net debt stands at 5.1B KRW. Fundamentals as of Jul 7, 2026
Our scenario range runs from 288.71 KRW (bear case) to 546.80 KRW (bull case); at 1,345 KRW, the current price sits above that range. The share trades about 52% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -38% fair-value upside — at -67%, 225220 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 7, 2026. TTM = trailing twelve months.
About the company
Genolution Inc. manufactures and sells IVD medical instruments in South Korea and internationally. Its products are primarily focused on molecular diagnostics, ribonucleic acid interference (RNAi) services, and double-stranded RNA (dsRNA) synthesis technology. The company offers Nextractor NX-Duo, Nextractor NX-32N/45N, Nextractor NX-Jr, Nextractor NX-24SA, NGS library preparation equipment, DNA/RNA extraction kits. It also develops and manufactures instruments and reagents for DNA/RNA; provides long dsRNA synthesis services; and siRNA/miRNA/shRNA synthesis service and related products. Genolution Inc. was founded in 2006 and is based in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Genolution Inc reported revenue of 9.4B KRW in FY2025 versus 72.8B KRW in FY2021, a compound −40.1%/yr. Reported net income was −11.6B KRW in FY2025.
Is 225220 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN34 | R$52.30 | R$9.67 | -82% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Genolution Inc (225220) undervalued?
What is the fair value of 225220?
What is the quality score of 225220?
What is the revenue of Genolution Inc (225220)?
What is the net profit margin of 225220?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.